Repligen Corporation's SEC filings document financial reporting, governance and public-company capital structure for a Nasdaq-listed life sciences company in bioprocessing technology. Recent Form 8-K reports attach earnings releases for quarterly and annual results, financial guidance and non-GAAP measures such as organic revenue, adjusted operating income, adjusted EPS and adjusted EBITDA.
The filing record also includes definitive proxy materials covering board matters, executive compensation and equity awards, along with Form 8-K disclosures on officer appointments, principal accounting officer responsibilities, financial reporting oversight and Sarbanes-Oxley-related infrastructure. Securities registration disclosures identify RGEN common stock, par value $0.01 per share, on the Nasdaq Global Select Market.
REPLIGEN CORP director Glenn P. Muir reported routine equity compensation awards. He received 995 restricted stock units, each representing one share of common stock, which vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual shareholder meeting.
Muir also received stock options covering 2,239 shares of common stock at an exercise price of $103.38 per share, expiring on May 14, 2036, with the same vesting schedule. Following these awards, he holds 40,051 shares of common stock directly and 2,239 stock options. The RSUs will be settled in shares after his service as a director ends, in line with his deferral election.
Repligen Corporation director Nicolas Barthelemy reported compensation-related equity grants. He was awarded 995 restricted stock units, each representing one share of Common Stock, and 2,239 stock options with an exercise price of $103.38 per share.
The RSUs and option award vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual shareholder meeting. Barthelemy has elected to defer settlement of the RSUs under Repligen’s Deferred Compensation Plan for Non-Employee Directors, with shares to be delivered after his service as a director ends. Following these grants, he directly holds 5,436 shares of Common Stock and 2,239 options.
Repligen Corporation reported the results of its 2026 Annual Meeting of Stockholders. As of the March 16, 2026 record date, 56,399,274 common shares were outstanding, and 54,022,359 were represented in person or by proxy, establishing a quorum.
Stockholders elected nine directors, each receiving more votes “for” than “against.” They also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
REPLIGEN CORP director Glenn P. Muir exercised stock options to acquire 2,434 shares of Common Stock. The options were exercised at $38.76 per share on May 7, 2026, and were fully vested and exercisable. Following the transaction, Muir directly holds 39,056 Common Stock shares. A corresponding derivative entry shows 2,434 Stock Option (Right to Buy) units exercised with an exercise price of $38.76 and an expiration date of May 18, 2027. No share sales or tax-withholding dispositions are reported in this Form 4.
Repligen Corp chief product officer Brian Robb had 334 common shares withheld on the release of restricted stock units, at a value of $126.43 per share. These shares were retained by the company to cover his tax obligations, not sold on the open market, leaving him with 7,985 shares held directly.
Repligen Corporation reports solid growth for the three months ended March 31, 2026, with total revenue of $194,255 (amounts in thousands), up 14.8% from 2025. Product revenue rose across all major franchises, including filtration, chromatography, process analytics and proteins.
Net income increased to $8,333, or $0.15 per diluted share, despite a $13,763 loss on the sale of Polymem S.A.S., which was partly offset by a $6,561 income tax benefit. Gross margin improved to 55.7% as higher volumes and mix more than covered cost increases.
Repligen ended the quarter with cash and cash equivalents of $582,650 and marketable securities of $201,881, supporting total assets of $2,930,772 and $600,000 principal of 1.00% Convertible Senior Notes due 2028. The company also began new restructuring initiatives and continues to work on remediating previously identified material weaknesses in internal control over financial reporting.
Repligen Corporation reported solid growth for the first quarter of 2026. Revenue reached $194.3M, up from $169.2M, a 15% increase, with 11% organic growth. GAAP diluted EPS rose to $0.15 from $0.10, while adjusted diluted EPS increased to $0.48 from $0.39.
GAAP gross margin was 55.7% and adjusted gross margin was 55.5%, with adjusted operating margin improving to 15.4%. Cash, cash equivalents and marketable securities totaled $785M at March 31, 2026. The company divested its non-core Polymem filtration business and launched a Transformation Office focused on margin expansion.
For full-year 2026, Repligen guides to adjusted revenue of $803M–$833M, implying 9%–13% reported and organic growth, and projects adjusted diluted EPS of $1.97–$2.05. Management also highlighted a new OEM partnership in China to expand local manufacturing access.
Repligen Corp Chief Executive Officer Olivier Loeillot sold 3,832 shares of common stock in an open-market transaction at $140 per share.
The sale was executed pursuant to a Rule 10b5-1 trading plan, and he continues to hold 54,246 shares of Repligen common stock directly after the transaction.
RGEN filed a Form 144 reporting a proposed resale of 3,832 common shares through Fidelity Brokerage Services LLC, with the filing dated 04/21/2026. The shares arise from restricted stock vesting: 616 shares vested 02/27/2026 and 3,216 shares vested 03/01/2026, both tied to compensation.
Repligen Corporation is soliciting proxies for its 2026 Annual Meeting, where shareholders will vote on three items: electing nine directors, ratifying Ernst & Young LLP as independent auditor for 2026, and approving a non-binding advisory vote on executive compensation.
The board is largely independent, with an independent Chair, fully independent key committees, proxy access rights, majority voting in uncontested elections, and stock ownership guidelines plus anti-hedging and anti-pledging policies. In 2025, Repligen reports 16% revenue growth on a reported and organic non‑COVID basis, driven mainly by consumables and cross‑selling to large biopharma and CDMO customers.
Adjusted operating margin reached 13.8% in 2025, up 0.9 percentage points, and adjusted gross margin expanded by about 2.2 percentage points. However, 2023 PSUs tied to 2023‑2025 Base Organic Revenue Growth and Adjusted ROIC paid out at 0%, reflecting 2.6% revenue growth and 4.4% Adjusted ROIC versus higher targets. CEO Olivier Loeillot’s 2025 total compensation was $6.1 million. As of March 16, 2026, Repligen had 56,399,274 shares outstanding, with the top institutional holders each owning over 5%.